Pharmetheus consultants and advisors present a unique collection of experiences and combination of skill sets.

Prof. Mats Karlsson, Advisor, COB
Dr. Marie Sandström, Senior Consultant, CEO
Dr. Elodie Plan, Senior Consultant, VP
Prof. Lena Friberg, Advisor
Dr. Andrew Hooker, Advisor
Prof. Ulrika Simonsson, Advisor
Dr. Martin Bergstrand, Senior Consultant
Dr. Niclas Jonsson, Senior Consultant
Dr. Mats Magnusson, Senior Consultant
Dr. Joakim Nyberg, Senior Consultant
Dr. Jakob Ribbing, Senior Consultant
Dr. Celine Sarr, Senior Consultant
Dr. Marcus Björnsson, Senior Consultant
Dr. Martin Fransson, Consultant
Dr. Chayan Acharya, Consultant
Dr. Sofia Friberg Hietala, Senior Consultant in Regulatory Clin Pharm and Pharmacometrics
Dr. Emma Hansson, Consultant
Dr. Erik Sjögren, Senior Consultant in PBPK and Biopharmaceutic modelling
Dr. Kajsa Harling, Senior Systems Developer
Dr. Anders Kristoffersson, Consultant
Arnaud Pharasyn, IT and Data Manager
Anna Olofsson, IT and Data Management Support
Emma Ångström, Finance and Administration Manager
Beatrice Attered, Communications Manager and Administrative Assistant

Prof. Mats Karlsson, Advisor, COB

  • Co-founder of Pharmetheus AB
  • Ph.D. in Pharmacokinetics and M.Sc. in Pharmaceutical Sciences
  • Professor of Pharmacometrics at the Pharmacometric Research Group, Uppsala University
  • Research focus on methodological development and application of pharmacometrics to drug development and drug usage
    • Leads a research group with >40 scientists, successfully supervised 35 students to their PhD, mentored >30 postdocs, published 250 peer-reviewed full-length research articles and is co-developer of 3 widely used pharmacometric software
  • Served as consultant to pharmaceutical industry for 20 years, and contributed with pharmacometric analyses to >20 successful filings for new drug applications in Europe and the US
  • Link to Mats Karlsson’s publications

Dr. Marie Sandström, Senior Consultant, CEO

  • Co-owner of Pharmetheus AB
  • Ph.D. in Pharmacokinetics and Drug Therapy and M.Sc. in Pharmaceutical Sciences
  • Experience as Lecturer and Associate Professor in Pharmacokinetics and Drug Therapy, Uppsala University, years 1997-2003
  • Experience in all clinical phases of Drug Development from AstraZeneca, years 2003-2013, as:
    • Clinical Pharmacometrician / Pharmacokineticist
    • Head of Clinical Pharmacology in Södertälje
    • Clinical Pharmacology & DMPK Projects Director in the therapeutic area of  Neuroscience
    • Global Director Clinical Pharmacometrics
  • Link to Marie Sandström’s publications

Dr. Elodie Plan, Senior Consultant, VP

  • Co-founder of Pharmetheus AB
  • Ph.D. in Pharmaceutical Biosciences, M.Sc. in Biostatistics and Pharm.D.
  • Research focus on investigating pharmacometric methods and developing novel models for discrete data
    • Therapeutic areas include Neurosciences -epilepsy, Alzheimer’s, pain, migraine, Parkinson’s, schiziophrenia-, Gastroenterology, and Women’s Health -endometriosis, uterine contractility-
    • Methodologies involve Markov models, time-varying hazards models, and repeated time-to-categorical events models
  • Experience as a Visiting Scientist, member of the Systems Biology group, at the contracting company Metrum Research Group, CT, USA
    • Development in a Bayesian framework of a semi-mechanistic model component predicting fracture rate in bone-related diseases
    • Support in consulting work -contribution to proposals, writing of reports, technical advices and pharmacometric analyses-
  • Pharmacometric tutoring performed at several workshops
  • Pharmacokinetic-pharmacodynamic modelling executed in collaboration with different pharmaceutical companies
  • Link to Elodie Plan’s publications

Prof. Lena Friberg, Advisor

  • Co-founder of Pharmetheus AB
  • Ph.D. in Pharmacokinetics and Drug Therapy and M.Sc. in Pharmaceutical Sciences
  • Professor in Pharmacometrics at the Pharmacometric Research Group, Uppsala University
  • Research focus on development of population PK and PD models for desired effects and adverse events
    • Therapeutic areas include bacterial infections, oncology, schizophrenia, rheumatoid arthritis, and QT-prolongation
    • Model-based translation of in vitro and animal PKPD to patients, and predictions from early to late phase development
  • Consultant to pharmaceutical industry:
  • Performed and advised on a wide range of PK and PKPD-modeling projects within bacterial and fungi infections, septic shock, endocrinology, oncology, rheumatoid arthritis, multiple sclerosis, schizophrenia, QT-prolongation and arrhythmia
  • Several of these projects have directly supported filing and interactions with EMA and FDA
  • Link to Lena Friberg’s publications

Dr. Andrew Hooker, Advisor

  • Co-founder of Pharmetheus AB
  • Ph.D. in Bioengineering, M.Sc. in Bioengineering, B.S. in Physics (Minor in Mathematics)
  • Associate professor at the Pharmacometric Research Group, Uppsala University
  • Degrees from University of Colorado, University of Washington (Seattle, USA), followed by post-doc at Uppsala University (Sweden).
  • Research ranges between methodological and applied pharmacometrics
    • Optimal experimental design
    • Methodological problems associated with building and evaluating Pharmacometric models
    • (Repeated) time-to-event model building
    • Development and use of PKPD models
    • Therapeutic areas include cancer, addiction, PET, biologics, etc.
  • Co-developer of a number of software programs including Xpose 4PsN, and the optimal design program PopED
  • 11 years experience as a consultant to pharmaceutical industry, including support and regulatory interactions leading to successful filings for new drug applications in Europe and the US
  • Link to Andrew Hooker’s publications

Prof. Ulrika Simonsson, Advisor

  • Co-founder of Pharmetheus AB
  • Ph.D. in Pharmaceutical Biosciences and M.Sc. in Pharmaceutical Sciences
  • Professor at the Pharmacometric Research Group, Uppsala University
  • Experience as post doc with Pharsight Corporation, CA, USA and as a pharmacometrician at AstraZeneca, Mölndal, Sweden
  • Research focus on how modelling and simulation of PK and PD can be used to optimize drug development and the link to personalized medicine
    • Was during 2012-2017  leading the modelling and simulation work within the European IMI funded consortium Predict-TB focusing on translation of pre-clinical to clinical of anti-tuberculosis drugs
  • More than 20 years of experience as a pharmacometric external consultant to drug development companies including regulatory interactions and filing
    • Patent pending for dosing nomograms based on Ulrika’s consultancy work
  • Therapeutic areas include tuberculosis, malaria, HIV, thrombosis/cardiovascular diseases, diabetes, insomnia, prostate cancer, hypertension, asthma and cortisol insufficiency
  • Link to Ulrika Simonsson’s publications

Dr. Martin Bergstrand, Senior Consultant

  • Co-founder of Pharmetheus AB
  • Ph.D. in Pharmaceutical Biosciences and M.Sc. in Biomedicine
  • Experience as clinical pharmacology research scientist at AstraZeneca R&D, Mölndal, Sweden Focus on phase I and II drug development within the field of metabolic disorders, e.g. diabetes.
    • Clinical drug development in phase I and II trials with multiple drug candidates ranging across several mechanisms of action
  • Extensive experience with mechanism based population PK modeling including complex absorption, non-linear elimination, enzyme induction and metabolite kinetics
  • Pharmacodynamic modeling in areas such as: Type II diabetes, Infectious disease, SLE (Lupus) and Oncology
  • Experience as contract researcher on behalf of several pharmaceutical companies
  • Link to Martin Bergstrand’s publications

Dr. Niclas Jonsson, Senior Consultant

  • Co-owner of Pharmetheus AB
  • Ph.D. in Pharmaceutical Biosciences and M.Sc. in Pharmaceutical Sciences
  • Associate Professor of Pharmacometrics at the Pharmacometrics Research group, Uppsala University
  • Experience as Senior Consultant at Exprimo NV and as Global Head of Modeling & Simulation at Roche:
    • Pharmacometric project management
    • Population PKPD modelling and simulation expert
    • Developer of methodology to manage large pharmacometric projects with critical time lines
  • Original developer of the software programs Xpose 4 and PsN
  • Link to Niclas Jonsson’s publications

Dr. Mats Magnusson, Senior Consultant

  • Co-owner of Pharmetheus AB
  • Ph.D. in Pharmaceutical Biosciences and M.Sc. in Pharmaceutical Sciences
  • Experience as Senior Consultant at Exprimo NV, and as Visiting Scientist of the Pharmacometrics groups at Pfizer:
    • Population PK/PD modelling, simulation and optimization of trials in paediatric populations
    • Mechanistic modelling of monoclonal antibodies
    • Benefit-risk assessment
    • Developer of methodology to manage large pharmacometric projects with critical timelines
    • Link to Mats Magnusson’s publications

Dr. Joakim Nyberg, Senior Consultant

  • Co-founder of Pharmetheus AB
  • Ph.D. in Pharmaceutical Biosciences and M.Sc. in Engineering Physics
  • Experience in system development and project management mainly with high security systems
  • Research focus on practical and methodological optimal design
    • Primary developer of the optimal design tool PopED
    • Worked with estimation methods for Pharmacometric models
    • Therapeutic areas include diabetes, oncology, immunosuppressant and QT-prolongations
  • Team leader for a large phase III study, involving project management, QA/QC processes and data security
  • Link to Joakim Nyberg’s publications

Dr. Jakob Ribbing, Senior Consultant

  • Co-owner of Pharmetheus AB
  • Ph.D. in Biopharmaceutical Sciences and M.Sc. in Pharmacy
  • Extensive experience as the Pfizer pharmacometrics subject-matter expert on Allergy and Respiratory disease (e.g. COPD, Asthma and Allergic Rhinitis)
  • Many applications of non-linear mixed effects modeling, to both individual-level (internal-trial) and aggregate level (literature-summary-level) data
  • Numerous applications of modeling for:
    • Setting target/hurdles for interim, trial or program continuation, or PoP/PoM/PoC declaration and transition
    • Making decisions on interim, trial or program continuation, or PoP/PoM/PoC declaration and transition, as well as dose/regimen selection, in various phases
    • Translation across populations and endpoints
    • Pharmacoeconomic simulations of real-life outcomes
  • Link to Jakob Ribbing’s publications

Dr. Celine Sarr, Senior Consultant

  • Ph.D. in Pharmaceutical Biosciences, M.Sc. in Biostatistics and Pharm.D.
  • Hospital Residency
  • Experience as Senior Consultant at Exprimo NV, as Senior expert modeler and cluster leader in the Modeling and Simulation group at Novartis:
    • Population PK/PD modelling and simulation e.g. Oncology
    • Project team, internal decision and submission support
    • Portfolio and operational management
  • DDMoRe scientific coordinator and product lead of the model repository
  • Link to Celine Sarr’s publications

Dr. Marcus Björnsson, Senior Consultant

  • Ph.D. in Pharmacokinetics and Drug Therapy and M.Sc. in Pharmaceutical Sciences
  • Experience as Senior Clinical Pharmacometrician and Neuroscience Therapy Area Pharmacometrics Expert at AstraZeneca
    • Population PK/PD modeling and simulation in a large number of drug development projects
    • Modeling of informative dropout
    • Experience from all phases of clinical drug development
  • Link to Marcus Björnsson’s publications

Dr. Martin Fransson, Consultant

  • Ph.D. in Medical Science and M.Sc. in Applied Physics and Electrical Engineering
  • Experience as Consultant of modeling and simulation in pharmacokinetics
  • Postdoctoral research in toxicokinetics
  • Research has focused on
    • Population PK modeling of anticancer drugs
    • PBPK modeling of heavy metals
  • Team leader and coordinator for IT work packages in European and Swedish infrastructure projects for biobanks, including project management, design of use-cases and information models for biobank databases
  • Link to Martin Fransson’s publications

Dr. Chayan Acharya, Consultant

  • Ph.D. in Pharmaceutical Sciences, M.Sc. in Physics, B.Sc. in Physics (Minor in Mathematics and Chemistry)
  • Former Postdoctoral Fellow at Uppsala University in Pharmacometrics research group
  • Research experience in Pharmacometrics includes:
    • Population PK/PD modeling and simulation and optimization of clinical trials
    • Developer of an R-package for population pharmacokinetic model diagnosis using non-compartmental analysis metrics
  • Therapeutic areas include immunosuppressant and pain management
  • Link to Chayan Acharya’s publications

Dr. Sofia Friberg Hietala, Senior Consultant in Regulatory Clin Pharm and Pharmacometrics

  • Ph.D. in Pharmacology and M.Sc. in Pharmacy
  • Experience as Senior Clinical Pharmacometrician at AstraZeneca
    • Pharmacokinetic/pharmacodynamic analyses in studies across all phases of clinical drug development
  • Pharmacokinetics and Pharmacometrics Assessor at the Swedish Medical Products Agency
    • Scientific assessment of marketing authorization applications, specifically regarding dose-finding, ADME properties, drug-drug interactions and special populations
    • Scientific advice and normative work (contributing to regulatory guidelines)
    • Former Vice-Chairperson of the Modelling and Simulation Working Group at the European Medicines Agency
  • Link to Sofia Friberg Hietala’s publications

Dr. Emma Hansson, Consultant

  • Ph.D in Pharmaceutical Biosciences and M.Sc in Pharmacy
  • Research experience in pharmacometrics includes:
    • Population PK/PD modeling and simulation in oncology
    • Development of an overarching PK/PD modeling framework in oncology, linking exposure, longitudinal biomarkers, adverse effects and treatment outcome
  • Pharmacometric tutoring performed at several workshops
  • Pharmacokinetic & Pharmacometric assessor at the Swedish Medical Products Agency
    • Scientific assessment of clinical pharmacology aspects, especially population PK and PK/PD analyses, as part of regulatory evaluation of Marketing Authorization Applications
    • Member of the expert group on modelling and simulation at the European Medicines Agency
    • Therapy areas covered include e.g. oncology, endocrinology and infectious diseases
  • Link to Emma Hansson’s publications

Dr. Erik Sjögren, Senior Consultant in PBPK and Biopharmaceutic modelling

  • Ph.D. in Pharmaceutics, M.Sc. in Pharmaceutical Sciences
  • Associate Professor in Biopharmaceutics at the Department of Pharmacy, Uppsala University
  • Post doc, absorption model development, at AstraZeneca, Mölndal, Sweden
  • Long research experience of applying mechanistic physiologically based modelling in areas such as:
    • Pharmacokinetics (PBPK)
    • Biopharmaceutics (PBBP and Drug delivery)
    • Intestinal absorption (mechanistic absorption modelling)
    • Hepatic disposition (transporters and enzymes)
  • Research in a wide scope of academic projects including supervision of Ph.D. students.
  • Experience as an external biopharmaceutical consultant to drug development companies including in silico model based support.
  • Link to Erik Sjögren’s publications

Dr. Kajsa Harling, Senior Systems Developer

  • Ph.D. in Scientific Computing and M.Sc. in Biotechnology Engineering from Uppsala University
  • Expertise in software development for pharmacometric modelling
  • Developer of PsN
  • Experience in algorithm development, numerical optimization and high performance computing

Dr. Anders Kristoffersson, Consultant

  • Ph.D in Pharmaceutical Biosciences and M.Sc in Molecular Biotechnology Engineering
  • Post doc with Hoffman-La Roche providing modelling and simulation in support of a new β-lactamase inhibitor
  • Research experience in pharmacometrics includes:
    • Clinical trial design
    • Population PK/PD modeling and simulation
    • Development of a framework for model based PK/PD modeling framework for antibiotic dose selection
  • Link to Anders Kristoffersson’s publications

Arnaud Pharasyn, IT and Data Manager

  • M.Sc. in Physics from the Ecole Normale Supérieure de Lyon
  • Experience as Consultant in the IT sector
  • Expertise in Software Development and Data Processing within Astrophysics, Electronics, Gaming industry, and Geophysics
  • Involved in the IT support to the personnel and students at the Geophysics department of Uppsala University
  • Responsible during more than 3 years for the maintenance of the IT infrastructure at the Swedish National Seismic Network

Anna Olofsson, IT and Data Management Support

  • M.Sc in Biotechnology Engineering from Uppsala University (minor in Bioinformatics)
    • Master’s thesis on biomarker analysis in cardiovascular disease
  • Experience with bioinformatic analysis of patient data

Emma Ångström, Finance and Administration Manager

  • B.Sc. in Business Administration and Economics from Uppsala University
  • Experience of working within finance and control since 1997, including positions as:
    • Auditor at PwC
    • Production Controller at Fresenius Kabi
    • Manager within Finance and Controlling at the Swedish Medical Products Agency

Beatrice Attered, Communications Manager and Administrative Assistant

  • M.Sc in Business Administration at Stockholm university and B.Sc in Political Science at Uppsala University (Minor in Marketing and Economics)
    • Master’s thesis on knowledge sharing within large and diverse organizations
  • Experience within marketing and administration
Menu